Sector News

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

August 7, 2015
Life sciences
Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan’s generics business for $40.5 billion. Mylan’s shares plummeted on that news. And now, Perrigo has broken its silence–and the word isn’t what Mylan wants to hear.
 
Perrigo CEO Joseph Papa stuck to his company’s prior stance that Mylan’s $205-per-share bid “substantially undervalues” its business–and “the market movement following Teva’s announcement last week only reinforced” that conviction, he said during the company’s Q2 earnings call.
 
And if Mylan shareholders vote–at a special meeting later this month–to push forward with the Perrigo deal anyway? “If they proceed with a tender offer for Perrigo, this will not be the easy path that some are painting it to be,” he said, pointing out that the bar for success in the tender offer process is 80% of all outstanding Perrigo shares. ” … We’ll make a strategic decision with the board about what’s the right thing to do for the company,” he said.
 
The way some analysts see it, that’s still a big “if.” As Leerink Partners’ Jason Gerberry wrote in a recent note to investors, Mylan would have to bring its bid to about $230 per Perrigo share to make an “acceptable” offer for its target. And even if it can muster that, the potential tie-up “does not appear to create any value at prices above $205,” Cowen & Co. analyst Ken Cacciatore wrote late last month.
 
Meanwhile, Mylan topped Q2 earnings forecasts Thursday, posting EPS of 91 cents–2 cents better than analysts expected. Revenue of $2.37 billion fell short of analysts’ $2.39 billion forecast, however, despite year-over-year growth of 29%.
 
By Carly Helfand
 

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend